Zentalis prices 23 million share offering at $3.50, expects $75.1 million net proceeds
Zentalis Pharmaceuticals entered an underwriting agreement on August 13, 2026 to sell 23,000,000 new common shares at $3.50 per share, before underwriting discounts. The company estimates net proceeds of about $75.1 million, which it plans to use for clinical trials, regulatory filings, manufacturing, pre-commercial activities and general corporate purposes. Shareholders face dilution from the new shares, and the underwriters also hold a 30-day option to buy up to 3,450,000 more shares.
Key points
- 23,000,000 shares offered at $3.50 per share, less underwriting discounts and commissions
- Estimated net proceeds of approximately $75.1 million after discounts and offering expenses
- Underwriters have a 30-day option to buy up to 3,450,000 additional shares
- Closing expected on August 17, 2026, subject to customary conditions
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.